Skip to main content
Erschienen in: Quality of Life Research 5/2009

01.06.2009

How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses

verfasst von: Peter M. Fayers, Madeleine T. King

Erschienen in: Quality of Life Research | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Excerpt

In 1988 the Lancet published a very large randomised clinical trial of intravenous streptokinase, oral aspirin, both, or neither for treatment of suspected acute myocardial infarction [1]. The ISIS-2 trial recruited 17,187 patients from 417 hospitals. The authors concluded that there were benefits both from streptokinase and from aspirin. This paper contained a complex table reporting subgroup analyses, and rather intriguingly, the first analysis was by astrological birth sign. The results suggested that for people born under the star signs Gemini and Libra, aspirin was no better than placebo; for others, aspirin had a strongly beneficial effect. Why, one might wonder, did a highly respected journal publish such arrant nonsense? …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360.
2.
Zurück zum Zitat Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMed Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMed
6.
Zurück zum Zitat Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.1016/j.jclinepi.2003.08.009.PubMedCrossRef Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.​1016/​j.​jclinepi.​2003.​08.​009.PubMedCrossRef
9.
Zurück zum Zitat Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.1001/jama.266.1.93.PubMedCrossRef Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.​1001/​jama.​266.​1.​93.PubMedCrossRef
10.
Zurück zum Zitat Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://www.hta.nhs.uk/fullmono/mon533.pdf. Accessed 12 March 2009. Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://​www.​hta.​nhs.​uk/​fullmono/​mon533.​pdf. Accessed 12 March 2009.
11.
Zurück zum Zitat Grouin, J.-M., Coste, M., & Lewis, J. (2005). Subgroup analyses in randomized clinical trials: Statistical and regulatory issues. Journal of Biopharmaceutical Statistics, 15, 869–882. doi:10.1081/BIP-200067988.PubMedCrossRef Grouin, J.-M., Coste, M., & Lewis, J. (2005). Subgroup analyses in randomized clinical trials: Statistical and regulatory issues. Journal of Biopharmaceutical Statistics, 15, 869–882. doi:10.​1081/​BIP-200067988.PubMedCrossRef
12.
Zurück zum Zitat Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.1056/NEJMsr077003.PubMedCrossRef Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.​1056/​NEJMsr077003.PubMedCrossRef
13.
Zurück zum Zitat Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRef Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRef
Metadaten
Titel
How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses
verfasst von
Peter M. Fayers
Madeleine T. King
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
Quality of Life Research / Ausgabe 5/2009
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-009-9473-3

Weitere Artikel der Ausgabe 5/2009

Quality of Life Research 5/2009 Zur Ausgabe